Abstract: A polymer electrolyte for a lithium secondary battery includes a polymer represented by Formula 1 below, wherein a and b are each independently an integer from 1 to 5, and n is an integer from 1 to 1,000. A lithium secondary battery includes the polymer electrolyte.

Abstract: A surface-treated cathode active material useful for manufacturing a lithium secondary battery have excellent output characteristics by performing a double coating with metal oxide and an electron and ion conductive polymerized copolymer on a surface of a cathode active material for a lithium secondary battery to enhance electrochemical properties and thermal stability of the cathode active material.

Abstract: A polymer electrolyte for a lithium secondary battery includes a polymer represented by Formula 1 below, wherein a and b are each independently an integer from 1 to 5, and n is an integer from 1 to 1,000. A lithium secondary battery includes the polymer electrolyte.

Abstract: A surface-treated cathode active material useful for manufacturing a lithium secondary battery have excellent output characteristics by performing a double coating with metal oxide and an electron and ion conductive polymerized copolymer on a surface of a cathode active material for a lithium secondary battery to enhance electrochemical properties and thermal stability of the cathode active material.

Abstract: A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.

Abstract: A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.

Abstract: A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.

Abstract: A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided: wherein: R1 represents naphthyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzothiazolyl, benzotriazolyl, benzooxazolyl, quinolinyl, or isoquinolinyl; wherein, R1 is optionally substituted at a substitutable position with one or more radicals independently selected from halogen, hydroxy, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, amino, monoalkylamino, and dialkylamino; R2 represents methyl or amino; and A, B, E, and D each independently represent carbon or nitrogen.

Abstract: A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.

Abstract: A 1,2,4-Triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.

Abstract: A novel crystalline organic acid salt of amlodipine having improved physiochemical properties, a preparation method thereof and a pharmaceutical composition comprising the same are provided.

Abstract: An alginate gel adsorbent to remove heavy metal ions according to the present invention is prepared by adding dropwisely 0.1-5 wt % alginate solution to a polyvalent cationic solution thereby cross-linking alginic acid with polyvalent cations. An alginate gel adsorbent containing activated carbon capable of simultaneously removing heavy metal ions and organotoxic materials, that is, activated carbon/alginate gel adsorbent, is prepared by adding dropwisely a mixed solution of 0.17-10 wt % of alginate and 0.1-10 wt % of activated carbon powder to a polyvalent cationic solution thereby cross-linking alginic acid with polyvalent cations in order to immobilize polyvalent cation to alginic acid containing activated carbon. The polyvalent cationic solution is selected from the group consisting of calcium chloride (CaCl2), strontium chloride (SrCl2), barium chloride (BaCl2) and aluminium chloride (AlCl3).

Abstract: The present invention relates to an isothiazole derivative of the following formula 1 or nontoxic salt thereof: wherein, R1 is hydrogen, alkoxy group or halogen group; R2 is methyl or amino group. According to the present invention, isothiazole derivative or nontoxic salt thereof having antipyretic, analgesic and antiphlogistic activity and an improved side effect; process for the preparation thereof; and pharmaceutical composition including the same can be provided.

Abstract: A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided: wherein, Ar represents naphthyl; 3,4-methylenedioxyphenyl: phenyl; or phenyl substituted with the group selected from C1-C6 alkyl, C1-C6 alkoxy, or halogen.

Abstract: Disclosed are a novel organic acid salt of amlodipine, its preparation method, and a pharmaceutical composition containing the same as a therapeutically active ingredient.

Abstract: A thiazolidine-4-one derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided: wherein: R1 and R2 each independently represent hydrogen, C1-C3 alkyl, halogen, methyl substituted with halogen, C1-C3 alkoxy substituted with halogen, cyano, or nitro.

Abstract: Disclosed are a novel organic acid salt of amlodipine, its preparation method, and a pharmaceutical composition containing the same as a therapeutically active ingredient.

Abstract: A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided: 1

Abstract: A 2-thioxothiazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided: wherein: R represents hydrogen or methyl; X represents hydrogen, methyl, halogen, nitro, or methanesulfonyl.

Abstract: The present invention relates to an isothiazole derivative of the following formula 1 or nontoxic salt thereof: 1